Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil

Imagem de Miniatura
Arquivos
art_MENDES-CORREA_Predictors_of_HBeAg_status_and_hepatitis_B_viraemia_2011.PDF (165.4 KB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Autores
MARTINS, Luiz G.
SILVA, Mariliza H.
UIP, David E.
Citação
BMC INFECTIOUS DISEASES, v.11, article ID 247, 8p, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: HBV-HIV co-infection is associated with an increased liver-related morbidity and mortality. However, little is known about the natural history of chronic hepatitis B in HIV-infected individuals under highly active antiretroviral therapy (HAART) receiving at least one of the two drugs that also affect HBV (TDF and LAM). Information about HBeAg status and HBV viremia in HIV/HBV co-infected patients is scarce. The objective of this study was to search for clinical and virological variables associated with HBeAg status and HBV viremia in patients of an HIV/HBV co-infected cohort. Methods: A retrospective cross-sectional study was performed, of HBsAg-positive HIV-infected patients in treatment between 1994 and 2007 in two AIDS outpatient clinics located in the Sao Paulo metropolitan area, Brazil. The baseline data were age, sex, CD4 T+ cell count, ALT level, HIV and HBV viral load, HBV genotype, and duration of antiretroviral use. The variables associated to HBeAg status and HBV viremia were assessed using logistic regression. Results: A total of 86 HBsAg patients were included in the study. Of these, 48 (56%) were using combination therapy that included lamivudine (LAM) and tenofovir (TDF), 31 (36%) were using LAM monotherapy, and 7 patients had no previous use of either one. Duration of use of TDF and LAM varied from 4 to 21 and 7 to 144 months, respectively. A total of 42 (48. 9%) patients were HBeAg positive and 44 (51. 1%) were HBeAg negative. The multivariate analysis revealed that the use of TDF for longer than 12 months was associated with undetectable HBV DNA viral load (serum HBV DNA level < 60 UI/ml) (p = 0. 047). HBeAg positivity was associated with HBV DNA > 60 UI/ml (p = 0. 001) and ALT levels above normality (p = 0. 038). Conclusion: Prolonged use of TDF containing HAART is associated with undetectable HBV DNA viral load. HBeAg positivity is associated with HBV viremia and increased ALT levels.
Palavras-chave
hepatitis B virus, HIV, virological outcome, tenofovir
URI
https://observatorio.fm.usp.br/handle/OPI/23739
Referências
  1. Alvarez-Uria G, 2009, HIV MED, V10, P269, DOI 10.1111/j.1468-1293.2008.00683.x
  2. Lacombe K, 2010, ANTIVIR THER, V15, P493, DOI 10.3851/IMP1495
  3. Soriano V, 2010, ANTIVIR RES, V85, P303, DOI 10.1016/j.antiviral.2009.10.021
  4. Benhamou Y, 2006, HEPATOLOGY, V43, P548, DOI 10.1002/hep.21055
  5. Gomes-Gouvea MS, 2009, J GEN VIROL, V90, P2638, DOI 10.1099/vir.0.013615-0
  6. Thio CL, 2002, LANCET, V360, P1921, DOI 10.1016/S0140-6736(02)11913-1
  7. Iloeje UH, 2006, GASTROENTEROLOGY, V130, P678, DOI 10.1053/j.gastro.2005.11.016
  8. Puoti M, 2006, J HEPATOL, V44, pS65, DOI 10.1016/j.jhep.2005.11.015
  9. Sitnik R, 2010, REV INST MED TROP SP, V52, P119, DOI [10.1590/50036-46652010000300001, 10.1590/S0036-46652010000300001]
  10. Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
  11. Konopnicki D, 2005, AIDS, V19, P593, DOI 10.1097/01.aids.0000163936.99401.fe
  12. Schmutz G, 2006, AIDS, V20, P1951, DOI 10.1097/01.aids.0000247116.89455.5d
  13. Mendes-Correa MC, 2010, J MED VIROL, V82, P1481, DOI 10.1002/jmv.21845
  14. Matthews GV, 2008, HEPATOLOGY, V48, P1062, DOI 10.1002/hep.22462
  15. Mendes-Correa M, 2010, EXPERT OPIN PHARMACO, V11, P2497, DOI 10.1517/14656566.2010.500615
  16. Lok ASF, 2009, HEPATOLOGY, V50, P661, DOI 10.1002/hep.23190
  17. Thio CL, 2009, HEPATOLOGY, V49, pS138, DOI 10.1002/hep.22883
  18. Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65
  19. Iser D. M., 2009, HIV Therapy, V3, P405, DOI 10.2217/HIV.09.19
  20. Avihingsanon Anchalee, 2010, Antivir Ther, V15, P917, DOI 10.3851/IMP1645
  21. BODSWORTH N, 1989, J INFECT DIS, V160, P577
  22. BONACINI M, 1991, AM J GASTROENTEROL, V86, P570
  23. Souza Milta Gomes de, 2004, Rev Soc Bras Med Trop, V37, P391, DOI 10.1590/S0037-86822004000500004
  24. European Association for the Study of the Liver, 2009, J HEPATOL, V50, P227, DOI 10.1016/J.JHEP.2008.10.001
  25. Gomes-Gouvea MS, 2008, ACTA TROP, V106, P149, DOI 10.1016/j.actatropica.2008.02.009
  26. Jain MK, 2007, J VIRAL HEPATITIS, V14, P176, DOI 10.1111/j.1365-2893.2006.00797.x
  27. LACOMBE K, 2009, C RETR OPP INF SAN F
  28. LADA O, 2008, 59 ANN M AM ASS STUD
  29. Lee T, 2009, HIV CLIN TRIALS, V10, P153, DOI 10.1310/hct1003-153
  30. Matthews GV, 2009, AIDS, V23, P1707, DOI 10.1097/QAD.0b013e32832b43f2
  31. Mendes-Correa Maria Cassia J., 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P81, DOI 10.1590/S0036-46652000000200004
  32. Monteiro Maria Rita de Cassia Costa, 2004, Rev Soc Bras Med Trop, V37 Suppl 2, P27, DOI 10.1590/S0037-86822004000700004
  33. Oliveira LH, 2001, MEM I OSWALDO CRUZ, V96, P635, DOI 10.1590/S0074-02762001000500007
  34. Peters MG, 2006, HEPATOLOGY, V44, P1110, DOI 10.1002/hep.21388
  35. Piroth L, 2007, AIDS, V21, P1323, DOI 10.1097/QAD.0b013e32810c8bcf
  36. Portelinha AM, 2009, MEM I OSWALDO CRUZ, V104, P960, DOI 10.1590/S0074-02762009000700003
  37. Quiros-Roldan E, 2008, ANTIVIR THER, V13, P341
  38. Sanchez LV, 2007, INTERVIROLOGY, V50, P9, DOI 10.1159/000096307
  39. Silva Adriana Cristina da, 2010, Mem Inst Oswaldo Cruz, V105, P770, DOI 10.1590/S0074-02762010000600007
  40. Sitnik R, 2007, BRAZ J MED BIOL RES, V40, P1689, DOI 10.1590/S0100-879X2007001200013
  41. Tovo Cristiane Valle, 2006, Arq Gastroenterol, V43, P73, DOI 10.1590/S0004-28032006000200002
  42. Tuma P, 2008, 59 ANN M AM ASS STUD
  43. Zago AM, 2007, BRAZ J INFECT DIS, V11, P475, DOI 10.1590/S1413-86702007000500007

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - LIM/39